Evidence map›Paper›PMID 40711446›Full record

ReviewBiotechnology journal2025

Challenges Associated With the Use of Metal and Metal Oxide Nanoparticles as Antimicrobial Agents: A Review of Resistance Mechanisms and Environmental Implications.

Mpho Phehello Ngoepe, Stiaan Schoeman, Saartjie Roux

Abstract readReview
In one paragraph

Review in Biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mpho Phehello NgoepeDSI-Mandela Nanomedicine Platform, Nelson, Mandela University, Gqeberha, Eastern Cape, South Africa.ORCID https://orcid.org/0000-0001-7682-9489
Stiaan SchoemanDSI-Mandela Nanomedicine Platform, Nelson, Mandela University, Gqeberha, Eastern Cape, South Africa.
Saartjie RouxDSI-Mandela Nanomedicine Platform, Nelson, Mandela University, Gqeberha, Eastern Cape, South Africa.

Funding

Department of Science and InnovationNelson Mandela University C2136/2021
6 · The paper itself

Abstract

The use of metal and metal oxide nanoparticles has been suggested as a means of combating antibiotic-resistant bacteria (ARB). This is due to the ability of nanoparticles to target numerous sites inside the bacterial cell. Microbes can, however, develop a resistance to hazardous environments. Soil microorganisms have evolved resistance to specific metals in soil by employing alternative survival strategies, like those adopted against antibiotics. Because of this survival mechanism, bacteria have been able to develop defense mechanisms to deal with metallic nanoparticles. Resistance has evolved in human pathogens to therapies that use metallic nanoparticles, such as silver nanoparticles. Metallic nanoparticles and antibiotics have currently been proven to be ineffective against several infections. Due to these concerns, scientists are investigating whether nanoparticles might cause environmental harm and potentially breed microbes that are resistant to both inorganic and organic nanoparticles. The increased use of inorganic nanoparticles has thus been shown to result in contaminations in wastewater, facilitating horizontal gene transfer among bacterial populations. The resistance mechanism of metallic nanoparticles, role in antibiotic resistance, and a potential solution to the environment's toxicity from nanoparticles are all discussed in this review.

Indexed as

Anti-Bacterial AgentsAnti-Infective AgentsBacteriaDrug Resistance, BacterialMetal NanoparticlesMetalsOxidesHumansAnti-Bacterial AgentsAnti-Infective AgentsMetalsOxidesbiogenicenvironmentinorganic nanoparticlemetal resistanceresistance genes

Identifiers

PMID40711446
PMCPMC12292745

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.